Clinical trials: Heart
Hypertension, Congestive Heart Failure
To Evaluate the Efficacy and Safety on Blood Pressure In Patients With Hypertension Diagnosed Congestive Heart Failure
To compare and evaluate the efficacy and safety of Candemore tab. versus Atacand tab. on blood pressure in patients with hypertension diagnosed congestive heart failure
- Trial name
- CANTABILE (NCT01682564)
- Testing
- Candemore tablet, Atacand tablet
- Where
- 14 sites in South Korea
- Volunteers
- 169 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Valvular Cardiac Surgeries
Dexmedetomidine Versus Midazolam-Fentanyl for Analgesia and Sedation
Postoperative sedation is an essential component in recovery of the patient undergoing cardiac surgery. It facilitates the patient's unawareness of the environment as well as reduce the discomfort and anxiety caused by surgery…
- Trial name
- NCT06464263
- Testing
- Dexmedetomidine
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Egymedicalpedia
Persistant Atrial Fibrillation
Ablation With the PFA System With a Large-Area Focal Catheter for the Treatment of Persistent Atrial Fibrillation
The study evaluates the safety and effectiveness of the investigational QuickShot Nav configuration of the CardioWave System for focal catheter ablation of persistent atrial fibrillation (PerAF).
- Trial name
- Quick AF (NCT07281521)
- Testing
- pulsed field ablation
- Where
- 3 sites in Croatia, Czechia
- Volunteers
- 200 people
- Sponsor
- CardioFocus
Heart Failure
Comparison of AV Optimization Methods Used in Cardiac Resynchronization Therapy (CRT)
The primary objective of SMART-AV is to assess the effect of SmartDelay for determining optimal AV delay timing during CRT compared to both a fixed AV delay and echocardiography-determined optimal AV timing chronically over a…
- Trial name
- SMART-AV (NCT00677014)
- Testing
- AV Delay programming through cardiac resynchronization therapy
- Where
- United States
- Volunteers
- 1,060 people
- Sponsor
- Boston Scientific Corporation
Heart Failure
Forxiga HF General Drug Use-Results Study
To capture safety when Forxiga is administered to patients with HF in clinical practice after launch.
- Trial name
- NCT04865406
- Where
- 45 sites in Japan
- Volunteers
- 1,221 people
- Sponsor
- AstraZeneca
Atrial Fibrillation (AF)
Bioequivalence Study of Dronedarone Hydrochloride Tablets in Healthy Subjects Under Fasting Conditions
The test formulation of Dronedarone Hydrochloride Tablets (400 mg) is bioequivalent to the reference formulation (MULTAQ®) in healthy Chinese subjects under fasting conditions.
- Trial name
- NCT07396506
- Testing
- Dronedarone Hydrochloride Tablets, MULTAQ® (Dronedarone Hydrochloride Tablets)
- Where
- China
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Cardiac Rhythm Disorder
EP Device Registry
This study will provide ongoing, high quality data on the safety, performance, and clinical benefits of Abbott's EP devices in a real-world setting.
- Trial name
- NCT04460209
- Testing
- Standard of Care
- Where
- 26 sites in Austria, Czechia and 8 more
- Volunteers
- 5,003 people
- Sponsor
- Abbott Medical Devices
Atrial Fibrillation
Patient Convenience Study- NIS RELATE
The aim of this non-interventional study is to describe patient's perception of anticoagulant treatment when using Pradaxa® to prevent stroke and systemic embolism while suffering from atrial fibrillation (according to its…
- Trial name
- NCT02849509
- Testing
- Pradaxa (dabigatran), Vitamin K antagonist
- Where
- 50 sites in Indonesia, Malaysia and 3 more
- Volunteers
- 1,313 people
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation
Treatment of Persistent Atrial Fibrillation With Sphere-9 Catheter and Affera Mapping and Ablation System
This is a prospective, multicenter, randomized clinical evaluation of the Sphere-9 Mapping and Ablation Catheter with the Affera Mapping and Ablation System.
- Trial name
- SPHERE Per-AF (NCT05120193)
- Testing
- Mapping and Ablation
- Where
- 23 sites in United States, Czechia and 1 more
- Volunteers
- 477 people
- Sponsor
- Medtronic Cardiac Ablation Solutions
Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
High-Density (HD) Wave Mapping in Subjects With Atrial Fibrillation as a Predictor of Recurrence After a Single Ablation Procedure Using a PVI-Only Strategy
The aim is to use the Advisor™ HD Grid Mapping Catheter, Sensor Enabled™ to characterize the atrial substrate and develop a model for predicting recurrence rates after a single procedure using a PVI only approach and a contact…
- Conditions
- Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation, Cardiac Arrhythmia
- Trial name
- WAVE-MAP AF (NCT03882021)
- Testing
- A specific electrophysiology mapping protocol is applicable with the GRID catheter.
- Where
- 15 sites in Austria, Czechia and 7 more
- Volunteers
- 300 people
- Sponsor
- Abbott Medical Devices
Severe Tricuspid Regurgitation
TRICUS STUDY Euro - Safety and Efficacy of the TricValve® Device
The TricValve® Transcatheter Bicaval Valves System is indicated for relief of tricuspid insufficiency in patients with symptomatic heart disease who are judged by a heart team, including a cardiac surgeon, to be at extreme risk…
- Trial name
- NCT04141137
- Testing
- TricValve® System
- Where
- 10 sites in Austria, Spain
- Volunteers
- 35 people
- Sponsor
- P+F Products + Features GmbH
Chronic Heart Failure (CHF)
A Prospective Evaluation of Natriuretic Peptide Based Referral of CHF Patients in Primary Care
This low interventional study, whose unique intervention was to measure the blood level of a biomarker called NT-proBNP in chronic heart failure patients daily followed-up by Primary Care Physicians (PCPs) in Europe, assessed if…
- Trial name
- PREFER (NCT02807857)
- Testing
- Standard care
- Where
- 191 sites in Belgium, Croatia and 16 more
- Volunteers
- 1,415 people
- Sponsor
- Novartis Pharmaceuticals
Atrial Fibrillation
Clinical Investigation of the LAmbre Left Atrial Appendage Closure System
The aim of the study LA-EU-01 was to examine the safety and the feasibility of the LAmbreTM Left Atrial Appendage Closure System in patients with non-valvular paroxymal, persistent or permanent atrial fibrillation, by using…
- Trial name
- NCT03122028
- Testing
- LAA closure system
- Volunteers
- 61 people
- Sponsor
- Lifetech Scientific (Shenzhen) Co., Ltd.
Atrial Fibrillation
Screening for Atrial Fibrillation (AF)-Potential Patients to Increase AF Detection Rate
To assess the prevalence of all (prevalent and paroxysmal) undiagnosed atrial fibrillation (AF) in a Japanese population with a moderate-to-high risk of stroke
- Trial name
- NCT03313167
- Testing
- Non-interventional
- Where
- Japan
- Volunteers
- 1,316 people
- Sponsor
- Bristol-Myers Squibb
Hypercholesterolemia, Coronary Heart Disease
Assessment of the Efficacy of Rosuvastatin in Patient Groups With a Dissimilar Risk Profile in an Observational Study (HEROS)
In an observational multi-centre study (HEROS), the effects of starting treatment with rosuvastatin were assessed, on low-density lipoprotein cholesterol (LDL-C) goal achievement, in patients with a dissimilar high-risk profile…
- Conditions
- Hypercholesterolemia, Coronary Heart Disease, Peripheral Vascular Disease, Cerebrovascular Accident
- Trial name
- HEROS (NCT00660764)
- Testing
- Rosuvastatin
- Sponsor
- AstraZeneca
Tachyarrhythmia
Lead EvaluAtion for Defibrillation and Reliability (LEADR) / Lead Evaluation for Defibrillation and Reliability in Left Bundle Branch Area Pacing (LEADR LBBAP)
The LEADR study is designed to assess the safety and efficacy of the Next Generation ICD lead. The LEADR LBBAP study is being conducted under the existing US FDA Investigational Device Exemption (IDE) for the Next Generation ICD…
- Trial name
- NCT04863664
- Testing
- Defibrillation (RV Implant), Defibrillation (LBBAP Implant)
- Where
- 55 sites in United States, Australia and 18 more
- Volunteers
- 998 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Obstructive Hypertrophic Cardiomyopathy
Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
This is a multicenter, international, double-blind study of the administration of mavacamten in participants with symptomatic obstructive HCM (oHCM).
- Trial name
- EXPLORER-HCM (NCT03470545)
- Testing
- mavacamten
- Where
- 71 sites in United States, Belgium and 11 more
- Volunteers
- 251 people
- Sponsor
- MyoKardia, Inc.
Coronary Artery Disease
First-in-man Trial Examining the Safety and Efficacy of BuMA Supreme and Resolute Integrity in Patients With de Novo Coronary Artery Stenosis
Prospective, multi-center, randomized 1:1, single blind trial using BuMA Supreme versus Resolute Integrity conducted in approximately 14 interventional cardiology centers in The Netherlands, Belgium, Spain and Portugal.
- Trial name
- NCT02236975
- Testing
- BuMA Supreme Biodegradable drug coating coronary stent system, Resolute Integrity durable polymer stent system
- Where
- 12 sites in Belgium, Netherlands and 2 more
- Volunteers
- 168 people
- Sponsor
- Sino Medical Sciences Technology Inc.
Atherosclerosis, Coronary Artery Disease
A Prospective, Multi-center Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™)
Compile acute (30-day) clinical outcomes data and 9-month angiographic and intravascular ultrasound (IVUS) data for the PROMUS Element™ Everolimus- Eluting Coronary Stent System in the treatment of patients with a single de novo…
- Trial name
- PLATINUM QCA (NCT00824434)
- Testing
- PROMUS Element™
- Where
- 17 sites in Australia, Malaysia and 2 more
- Volunteers
- 100 people
- Sponsor
- Boston Scientific Corporation
Aortic Stenosis
Safety and Efficacy of TaurusOne® Transcatheter Aortic Valve Replacement System With Retrievable Delivery Catheter System
The TaurusOne® transcatheter aortic valve system with retrievable delivery catheter system is evaluated the safety and effectiveness for the delivery of artificial aortic valve in a prospective, multicenter, single-arm clinical…
- Trial name
- NCT04744857
- Testing
- The experimental apparatus consisted of artificial aortic valve, transporter and grip-loading system.
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Peijia Medical Technology (Suzhou) Co., Ltd.